A Vaccines Renaissance, Spurred By COVID-19, Is Underway
The pandemic has reignited interest and investment in vaccines across a wide array of disease areas by big pharma and venture investors, a panel of BIO experts said.
You may also be interested in...
The company is focusing on new technologies, including mRNA, and expects the vaccines business to deliver a high single-digit sales CAGR over the next five years.
The successor to Pfizer’s 13-valent pneumococcal vaccine, a lynchpin of the company's lifecycle management strategy, was approved in the US.
Pfizer said it expects to generate $26bn in annual revenues from the COVID-19 vaccine BNT162b2 and is leveraging the platform to build out a durable business.